Larvol Delta - A-Phase-III-Clinical-Study-to-Evaluate-the-Protective-Efficacy-Safety-and-Immunogenicity-of-a-SARSCoV2-Messenger-Ribonucleic-Acid-mRNA-Vaccine-Candidate-in-Population-Aged-18-Years-and-Above

ARCoV - Walvax, Academy of Military Medical Sciences, Suzhou Abogen Biosci

http://clinicaltrials.gov/ct2/show/NCT04847102

Apr 15, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev